47 results about "Tumor Load" patented technology

The present disclosure provides methods and systems for screening or detecting a colorectal cancer or following colorectal disease progression that may be applied to cell-free nucleic acids such as cell-free DNA. The method may use detection of methylation signals within a single sequencing read in identified genomic regions as input features to train a machine learning model and generate a classifier useful for stratifying populations of individuals. The method may comprise extracting DNA from a cell-free sample obtained from a subject, converting the DNA for methylation sequencing, generating sequencing reads, and detecting colon proliferative cell disorder-associated signals in the sequencing information and training a machine learning model to provide a discriminator capable of distinguishing groups in a subject population such as healthy, cancer or distinguishing disease subtype or stage. The method may be used for, e.g., predicting, prognosticating, and / or monitoring response to treatment, tumor load, relapse, or colorectal cancer development.

The invention discloses application of sorafenib in maintenance treatment of acute myelogenous leukemia after transplantation, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: it is found for the first time that secretion and killing functions of NK cells can be enhanced by using sorafenib for maintenance treatment after transplantation; sorafenib enhances communication between macrophages and NK cells by promoting secretion of macrophage proinflammatory factors, so that the function of NK cells is enhanced. The invention clarifies that sorafenib enhances the GVL effect of NK cells in a low tumor load environment, discusses the molecular mechanism of sorafenib for enhancing the NK cell function by promoting macrophage metabolism reprogramming, and provides a new thought for maintaining precision and optimization of treatment after transplantation.

The present application relates to the field of intelligent medical treatment, in particular to a tumor treatment dosing regimen Pareto optimization method based on forward-backward stochastic differential equation. The present application unifies the terminal tumor load, dosing cost and treatment risk into the same stochastic control framework, can establish the Pareto optimality condition corresponding to the nonlinear model, and further converts into the implementable closed-loop state feedback control law in the LQ case. Through the combination with the numerical example and the Pareto frontier analysis, an implementable, interpretable and scalable technical path is provided for the multi-objective individualized treatment regimen design, which can solve the problem that the existing technology is difficult to uniformly process the terminal therapeutic effect, dosing consumption and cumulative risk, and difficult to obtain the implementable closed-loop feedback strategy under the forward-backward stochastic control framework.

Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor.The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

The application discloses biomarkers for early diagnosis of lung adenocarcinoma and / or classification of unknown lung nodules and application thereof, and relates to the technical field of biological medicine.The biomarkers are piR-hsa-8429916 or piR-hsa-8393202.Two core biomarkers, piR-hsa-8393202 and piR-hsa-8429916, are successfully identified by screening and verifying piRNAs differentially expressed in lung adenocarcinoma tissues and serum, and the expression levels of the biomarkers are significantly positively correlated with tumor load.The diagnostic value of piR-hsa-8393202 and piR-hsa-8429916 in early diagnosis of lung adenocarcinoma and classification of lung nodules is significantly better than that of a traditional CEA marker.The application provides an innovative solution for early diagnosis of lung adenocarcinoma and risk stratification of lung nodules.

The present application relates to the field of liver cancer immunotherapy efficacy evaluation method combining imageomics and deep learning, and specifically discloses a liver cancer immunotherapy efficacy evaluation method combining imageomics and deep learning. The method comprises the following steps: acquiring multi-modal medical images and clinical information of a liver cancer patient; performing standardization preprocessing and automatic lesion segmentation on the images; extracting features through a multi-scale deep network and realizing semantic alignment by using a cross-modal attention mechanism; fusing the images and the clinical data to construct a multi-source heterogeneous feature matrix; adopting a hierarchical model structure, modeling the spatial distribution of tumor immune microenvironment by using a graph neural network at the bottom layer, dynamically tracking the evolution of efficacy by using a gated recurrent unit at the upper layer, and finally outputting an immune response probability, a tumor load trend and a treatment response grade. The present application can objectively and quantitatively evaluate the efficacy of liver cancer immunotherapy, and improve the precision and automation level of individualized diagnosis and treatment decision-making.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The present disclosure provides a probe set for judging the systemic tumor burden of triple-negative breast cancer and application thereof, the probe set provided by the present disclosure can be used for detecting the gene markers of triple-negative breast cancer and for evaluating the systemic tumor burden, and can achieve good coverage and capture of the target region, obtain sufficient read information on the target region, and overcome the spatial and temporal heterogeneity of tumors to a certain extent, while improving the capture efficiency, stabilizing the experimental system, and meeting the requirements of clinical detection.

The invention belongs to the technical field of medicine, and discloses an application method of tumor-killing effect B cells in colorectal cancer liver metastasis, Meta-CBL is used for transforming the B cells into tumor-killing effect cells for the first time, and the anti-tumor immune effect is remarkably enhanced. In a tumor microenvironment, the meta-CBL can directly kill tumor cells and activate other effector immune cells, so that synergistic anti-tumor is realized. By combining liquid biopsy and single cell sequencing, tumor load and microenvironment immune state can be tracked in real time. The evaluation precision is higher than that of traditional iconography, invalid treatment patients can be recognized in the early stage, and the treatment strategy is adjusted in time. Precise treatment and dynamic prognosis evaluation of colorectal cancer liver metastasis are realized by innovatively utilizing meta-CBL, and the defects of limited treatment effect and lagging evaluation means in the prior art are overcome. The comprehensive system structure and the precise treatment strategy of the system bring brand new treatment choices and remarkable survival benefits for patients with colorectal cancer liver metastasis, and the system has extremely high industrialization and clinical popularization value.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The invention provides an antisense oligonucleotide (ASO), the antisense oligonucleotide is complementary with a CREPT gene sequence, the expression of CREPT can be effectively inhibited, and the antisense oligonucleotide is selected from antisense oligonucleotides with any one nucleotide sequence as shown in SEQ ID No.1-3. The antisense oligonucleotide (ASO) can efficiently and specifically target CREPT, the expression level of CREPT in tumor cells is significantly reduced, the clone formation ability of the tumor cells is further reduced, and the invasion ability of the tumor cells is significantly reduced. The invention further provides an extracellular vesicle and a pharmaceutical composition, and tumor load can be remarkably reduced after the extracellular vesicle is applied to a patient. The antisense oligonucleotide (ASO) of the invention can be used for treating liver cancer.

The invention discloses a probe set for evaluating pancreatic cancer whole-body tumor load and application thereof.The probe set comprises probes used for detecting gene markers, the gene markers comprise KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, high-frequency and medication-related sites of pancreatic cancer are covered, targeted capture is conducted on plasma ctDNA independently or when the probe set and a personalized probe set are used in an overlapped mode, and the pancreatic cancer whole-body tumor load is evaluated. And the whole-body tumor load of the pancreatic cancer patient is dynamically monitored in real time.

The present application relates to the biomedical technology field, and is an inhibitor targeting CCDC137 gene and application thereof in preparation of a drug for diagnosing and treating acute myeloid leukemia, wherein the inhibitor targeting CCDC137 gene is shRNA. The present application discloses, for the first time, that CCDC137 gene is a new therapeutic target and a prognostic biomarker for acute myeloid leukemia. Experiments prove that inhibition of CCDC137 gene can significantly reduce AML cell proliferation, prolong the survival of an animal model, and reduce tumor load. Based on this finding, the present application provides a therapeutic strategy for treating AML by inhibiting the expression of CCDC137 gene, provides a new therapeutic strategy for AML patients, and reduces the recurrence cost through targeted therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted beta-catenin palmitoylation small-molecule inhibitor and application thereof in treatment of colorectal cancer. The application of beta-cat-Oxazole in preparation of the medicine for treating the colorectal cancer is provided for the first time, the beta-cat-Oxazole can specifically target an interaction interface (residues near C466) of ZDHHC5 and beta-catenin, and other functions or normal physiological signal channels of the beta-catenin are not affected. Due to the accuracy, the miss-target risk is remarkably reduced, and a treatment window is wider. The compound can be used as a single drug in a preclinical model to significantly inhibit tumor growth; in an AOM / DSS induced colorectal cancer model, the tumor load is reduced by about 50%. In addition, the invention discloses a core mechanism of a targeted ZDHHC5-beta-catenin interaction interface, and a new structural basis is provided for subsequent drug target design.

Embodiments of the present disclosure pertain to methods of assessing glioma in a subject by (1) receiving a plurality of measured biomarker levels of the subject; and (2) assessing glioma in the subject based on the measured biomarker levels by at least correlating differentially expressed levels of the measured biomarkers to at least one of (a) diagnosis of glioma, (b) progression of glioma, (c) treatment outcome, and / or (d) tumor burden. The methods of the present disclosure also include a step of (3) making a treatment decision based on the assessment. Additional embodiments of the present disclosure pertain to systems for assessing glioma in a subject.

The present disclosure provides methods and systems for detecting colorectal cancer by nucleic acid methylation analysis. In particular, the present disclosure provides methods and systems for screening or detecting colorectal cancer or subsequent colorectal disease progression, which can be applied to cell-free nucleic acids, such as cell-free DNA. The method may train a machine learning model using detection of methylation signals within a single sequencing read in an identified genomic region as an input feature and generate a classifier suitable for layering a population of individuals. The method may include extracting DNA from a cell-free sample obtained from a subject, transforming the DNA for methylation sequencing, generating a sequencing read, and detecting a colonic proliferative cell disorder related signal in sequencing information, and training a machine learning model to provide a discriminator, the discriminator is capable of differentiating groups, such as health, cancer, or differentiating disease subtypes or stages, in a population of subjects. The methods are useful, for example, in predicting, prognosing, and / or monitoring response to treatment, tumor load, recurrence, or progression of colorectal cancer.

The application discloses an siRNA targeting ACADL, a lipid nanoparticle containing the same and application thereof. The application also relates to a pharmaceutical composition containing the lipid nanoparticle and use of an agent for inhibiting ACADL in preparation of a drug for treating peritoneal metastasis of colorectal cancer. The siRNA and the lipid nanoparticle containing the same can effectively inhibit cancer cell proliferation and invasion, reduce tumor load of peritoneal metastasis foci and have the advantages of selectively knocking down tumor ACADL expression and reducing systemic toxicity by targeting inhibition of a fatty acid oxidation (FAO) process of tumor cells.

The application discloses a biomarker for prognosis evaluation of extrahepatic cholangiocarcinoma, a prognosis risk evaluation system and application, and belongs to the technical field of bioinformatics. The application adopts the combination of miR-34c-5p, miR-100-5p, miR-193b-5p, miR-122-5p, miR-5588-5p and miR-122-3p as a biomarker, can effectively improve the accuracy of differential diagnosis of extrahepatic cholangiocarcinoma, can distinguish extrahepatic cholangiocarcinoma patients from healthy people and benign biliary disease patients with high precision, and overcomes the limitation that traditional tumor markers such as CA19-9 are prone to false positive results in benign biliary diseases. Meanwhile, the expression level change of the biomarker combination can dynamically reflect the postoperative tumor load change, and is helpful for accurately evaluating the surgical effect.

The invention discloses an in-vivo evaluation method for the curative effect of NK cells on human ovarian cancer ascites tumor, which comprises the following steps: inoculating human ovarian cancer cells into the abdominal cavity of a female healthy mouse, and establishing a nude mouse model of the human ovarian cancer ascites tumor; nude mouse models are grouped, and intraperitoneal injection administration is carried out on each group of mice; and carrying out fluorescence tracing on the dosed mouse by adopting a fluorescence imaging method, observing the health and death conditions of the mouse at the same time, and judging the treatment effect of the NK cells on the human ovarian cancer ascites tumor. An ovarian cancer mouse model is established through intraperitoneal injection of an SK-OV-3 cell strain, the treatment effect of NK cells on human ovarian cancer ascites tumor in an in-vivo peritoneal complex environment is evaluated, the result is closer to the actual situation, and the detection result is accurate. The compound is applied to preparation of medicines for treating human ovarian cancer ascites tumor, and can significantly prolong the lifetime, reduce the death rate, reduce the tumor load and improve the life quality.

The invention discloses siRNA (small interfering Ribonucleic Acid) for inhibiting the expression of a CREPT gene. The nucleotide sequence of a positive-sense strand of the siRNA is shown as any one of SEQ ID No. 1 to SEQ ID No. 3. The siRNA can be used for inhibiting CREPT (Cathode Reactive Part of siRNA can inhibit the growth of mouse colon cancer cells and the growth of NIH3T3 fibroblast cells. And the drug can be delivered through the liposome of the delivery system si-CREPT, so that the mouse liver cancer can be treated, and the tumor load of the mouse liver cancer can be remarkably reduced.

The invention disclosed herein generally relates to methods of assessing and monitoring tumor load through analysis of tumor DNA in cancer patients. Quantitative measures derived from cell-free DNA and germline DNA are used to assess and monitor tumor load. By assessing and monitoring tumor load, cancer may be detected in a subject. The tumor load of a subject may be assessed at a number of different time points to monitor a progression, regression, or recurrence of cancer in a subject.

The invention discloses a biological system based on metabolic affinity and application of the biological system in preparation of antitumor drugs and detection kits. According to the system, selective metabolic affinity screening is carried out based on living microorganisms through an in-vitro adaptability protocol, and selective recognition of a tumor microenvironment, local generation of a bioactive agent and biological restraint are achieved. The system integrates chemotropism detection of tumor metabolic markers, biologic and adaptive decision based on nutritional gradients, controlled production of biologically active metabolites, and a safety architecture. And the self-amplification treatment effect in proportion to the tumor load is realized through a nutrition chemical trend mechanism. The invention aims to eliminate systemic toxicity of traditional chemotherapy through concentration gradient mediated super localized release, reduce production cost through controlled self-replication in continuous flow biological reaction, and guarantee safety through immune clearance. Affinity can be obtained through a metabolic adaptation experiment, the method is suitable for various tumors through a modular reselection protocol, and a new direction is provided for metastatic cancer treatment.

The application relates to the technical field of medical data processing, and discloses an osteosarcoma prognosis risk prediction system. The osteosarcoma prognosis risk prediction system is constructed by integrating non-invasive and easily-obtained multi-dimensional clinical data (including demographic and baseline clinical data, tumor load and malignancy data, and serum tumor marker data) and training an optimized machine learning model (such as a random forest). The osteosarcoma prognosis risk prediction model and system can realize early warning, real-time monitoring and accurate grading, can realize early, real-time and non-invasive evaluation and grading early warning of the prognosis risk of patients, solve the problems that existing monitoring means are lagging, invasive and cannot be frequently performed, provide objective and quantitative basis for clinical identification of high-risk patients and development of individualized strategies, and provide strong technical support for improvement of the management and prognosis of osteosarcoma patients.

The invention belongs to the field of biological medicine, and relates to a recombinant VAR2CSA, which can be used for detecting specific types of tumor-type chondroitin sulfate (ofCS) and proteoglycan (ofCSPG) modified by the tumor-type chondroitin sulfate (ofCS). The recombinant VAR2CSA disclosed by the invention has relatively high binding affinity with chondroitin sulfate A (CSA), and the tumor type chondroitin sulfate constructed by the recombinant VAR2CSA disclosed by the invention and a detection method of proteoglycan modified by the tumor type chondroitin sulfate have a detection effect on all malignant tumors expressing the CSA. The tumor-type chondroitin sulfate based on the recombinant VAR2CSA and a detection method of proteoglycan modified by the tumor-type chondroitin sulfate can be used for early screening and diagnosis of tumors, tumor load monitoring and prognosis prediction.

The application relates to application of BAHD1 as a target point in preparation of a leukemia treatment drug and belongs to the technical field of biological medicine. In order to solve the problems of high drug resistance and high recurrence of an acute leukemia treatment scheme, the application provides application of BAHD1 as a target point in preparation of a leukemia treatment drug. It is proved that BAHD1 is highly expressed in acute leukemia cells, and is used as a molecular marker for diagnosis of acute leukemia. It is proved that knocking out BAHD1 can significantly inhibit proliferation and self-renewal of the acute leukemia cells, promote apoptosis and differentiation of the acute leukemia cells, effectively inhibit proliferation of leukemia cells in the body, reduce tumor load and extramedullary infiltration, and significantly prolong the survival period. In addition, knocking out BAHD1 can significantly enhance the sensitivity of the acute leukemia cells to traditional chemotherapy drugs and targeted treatment drugs.

The present disclosure in one aspect provides technologies for detection of liver cancer, e.g., early detection of liver cancer. In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to liver cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

This patent discloses a method for detecting a patient's tumor burden. DNA is extracted from a patient's tumor tissue sample, a predetermined number of biomarker genes are selected to form a biomarker gene cluster ("customized gene cluster"). A DNA sample of circulating free cells in the patient's body fluid is isolated. DNA sequences containing biomarker genes are enriched in the free DNA fragments. The enriched DNA is sequenced. The mutant and normal DNA sequences in the enriched DNA are counted. The patient's tumor burden is then determined. Preferably, mutations in therapeutically relevant genes ("drug-targeted genes") are detected simultaneously with the detection of the customized gene cluster.

The invention relates to the technical field of biological medicines, in particular to an application of Alzvudine in tumor prevention. Studies show that the alzovudine can inhibit tumor immune escape, reduce the number of tumors, reduce tumor load and inhibit tumor growth, so that the alzovudine has a good prevention effect on intestinal cancer and melanoma. The alzovudine is good in curative effect, low in toxic and side effects and suitable for long-term administration of patients.

The invention belongs to the field of medical treatment, and discloses an application of 11-MT in medicine preparation. The medicine refers to a medicine for treating acute B lymphocytic leukemia. Researches show that 11-MT shows the following advantages in treatment of acute B lymphocytic leukemia: in an in-vitro test, 11-MT significantly promotes apoptosis of BALL-1 cells and shows dose dependence, 11-MT significantly promotes generation of ROS in the BALL-1 cells and shows dose dependence, 11-MT can cause DNA damage of the BALL-1 cells and shows dose dependence, and in an in-vivo test, 11-MT can significantly promote apoptosis of the BALL-1 cells and shows dose dependence. The 11-MT has a regulating effect on specific organ lesions, shows good repairing and protecting effects, can recover multiple serum biochemical indexes abnormally increased due to tumor load to a normal level, and can well reduce tumor cell infiltration.

This invention relates to the preparation and application of an oncolytic virus that specifically promotes the rupture of tumor cell plasma membranes. Specifically, this invention utilizes a glioblastoma-specific Nestin enhancer or a tumor cell-specific Survivin promoter to drive the specific expression of the NINJ1 or DTA gene, thereby enhancing the lytic and killing ability of cells. The oncolytic virus G005 expressing NINJ1 exhibits strong killing ability against tumor cells, and the tumor completely disappears in an orthotopic glioma animal model. It can also rapidly restore the weight loss in mice caused by tumor burden, demonstrating that the oncolytic virus G005 has excellent therapeutic effects against GBM.